Pharmacologic Agents for Mucus Clearance in Bronchiectasis

Clinics in Chest Medicine

Volumn 33, Issue 2, 2012, Pages 363-370

  Nair, Girish B ^a   Ilowite, Jonathan S ^b  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Bronchiectasis; Hyperosmolar agents; Hypertonic saline; Inhaled mannitol; Mucociliary clearance

Indexed keywords

ACETYLCYSTEINE; DORNASE ALFA; ERDOSTEINE; FORMOTEROL; GUAIFENESIN; MANNITOL; PLACEBO; SODIUM CHLORIDE; TERBUTALINE;

BREATHING EXERCISE; BRONCHIECTASIS; BRONCHOSPASM; BRONCHUS MUCUS; COMBINATION CHEMOTHERAPY; COUGHING; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEMOPTYSIS; HUMAN; LUNG CLEARANCE; MUCOCILIARY CLEARANCE; MUCUS SECRETION; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SORE THROAT;

ADMINISTRATION, INHALATION; BRONCHIECTASIS; EXPECTORANTS; HUMANS; MANNITOL; MUCOCILIARY CLEARANCE; SALINE SOLUTION, HYPERTONIC; TREATMENT OUTCOME;

EID: 84861533524     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2012.02.008     Document Type: Review

References (40)

1. Weycker D., Edelsberg J., Oster G., et al. Prevalence and economic burden of bronchiectasis. Clin Pulm Med 2005, 12:205-209.
2. Ilowite J., Spiegler P., Chawla S. Bronchiectasis: new findings in the pathogenesis and treatment of this disease. Curr Opin Infect Dis 2008, 21:163-167.
3. Wanner A., Salathé M., O'Riordan T.G. Mucociliary clearance in the airways. Am J Respir Crit Care Med 1996, 154:1868-1902.
4. Daviskas E., Anderson S.D. Hyperosmolar agents and clearance of mucus in the diseased airway. J Aerosol Med 2006, 19:100-109.
5. Fahy J.V., Dickey B.F. Airway mucus function and dysfunction. N Engl J Med 2010, 363:2233-2247.
6. Voynow J.A., Rubin B.K. Mucins, mucus, and sputum. Chest 2009, 135:505-512.
7. Tarran R., Grubb B.R., Gatzy J.T., et al. The relative roles of passive surface forces and active ion transport in the modulation of airway surface liquid volume and composition. J Gen Physiol 2001, 118:223-236.
8. Rubin B.K. Mucolytics, expectorants, and mucokinetic medications. Respir Care 2007, 52:859-865.
9. Matsui H., Verghese M.W., Kesimer M., et al. Reduced three-dimensional motility in dehydrated airway mucus prevents neutrophil capture and killing bacteria on airway epithelial surfaces. J Immunol 2005, 175:1090-1099.
10. Rogers D.F. Mucoactive agents for airway mucus hypersecretory diseases. Respir Care 2007, 52:1176-1193.
11. Foster W.M. Mucociliary transport and cough in humans. Pulm Pharmacol Ther 2002, 15:277-282.
12. King M. Mucoactive therapy: what the future holds for patients with cystic fibrosis. Pediatr Pulmonol 1997, 24:122-123.
13. Silber G., Proud D., Warner J., et al. In vivo release of inflammatory mediators by hyperosmolar solutions. Am Rev Respir Dis 1988, 137:606-612.
14. Jongejan R.C., de Jongste J.C., Raatgeep R.C., et al. Effects of hyperosmolarity on human isolated central airways. Br J Pharmacol 1991, 102:931-937.
15. Wong L.B., Miller I.F., Yeates D.B. Pathways of substance P stimulation of canine tracheal ciliary beat frequency. J Appl Physiol 1991, 70:267-273.
16. Metersky M.L. New treatment options for bronchiectasis. Ther Adv Respir Dis 2010, 4:93-99.
17. Daviskas E., Anderson S.D., Eberl S., et al. Effect of increasing doses of mannitol on mucus clearance in patients with bronchiectasis. Eur Respir J 2008, 31:765-772.
18. Daviskas E., Anderson S.D., Brannan J.D., et al. Inhalation of dry-powder mannitol increases mucociliary clearance. Eur Respir J 1997, 10:2449-2454.
19. Daviskas E., Anderson S.D., Eberl S., et al. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am J Respir Crit Care Med 1999, 159:1843-1848.
20. Daviskas E., Anderson S.D., Eberl S., et al. The 24-h effect of mannitol on the clearance of mucus in patients with bronchiectasis. Chest 2001, 119:414-421.
21. Daviskas E., Anderson S.D., Eberl S., et al. Effects of terbutaline in combination with mannitol on mucociliary clearance. Eur Respir J 2002, 20:1423-1429.
22. Daviskas E., Anderson S.D., Young I.H. Effect of mannitol and repetitive coughing on the sputum properties in bronchiectasis. Respir Med 2010, 104:371-377.
23. Courtney J.M., Kelly M.G., Watt A., et al. Quality of life and inflammation in exacerbations of bronchiectasis. Chron Respir Dis 2008, 5:161-168.
24. Daviskas E., Anderson S.D., Gomes K., et al. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum. Respirology 2005, 10:46-56.
25. Bilton D., Robinson P., Cooper P., et al. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J 2011, 38(5):1071-1080.
26. Koskela H.O., Hyvärinen L., Brannan J.D., et al. Coughing during mannitol challenge is associated with asthma. Chest 2004, 125:1985-1992.
27. Elkins M.R., Robinson M., Rose B.R., et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006, 354:229-240.
28. Donaldson S.H., Bennett W.D., Zeman K.L., et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006, 354:241-250.
29. Wills P., Greenstone M. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst Rev 2006, 2. CD002996.
30. Kellett F., Redfern J., Niven R.M. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. Respir Med 2005, 99:27-31.
31. Grandjean E.M., Berthet P., Ruffmann R., et al. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther 2000, 22:209-221.
32. Decramer M., Rutten-van Molken M., Dekhuijzen P.N., et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Lancet 2005, 365:1552-1560.
33. Fuchs H.J., Borowitz D.S., Christiansen D.H., et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994, 331:637-642.
34. Wills P.J., Wodehouse T., Corkery K., et al. Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability. Am J Respir Crit Care Med 1996, 154:413-417.
35. O'Donnell A.E., Barker A.F., Ilowite J.S., et al. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. Chest 1998, 113:1329-1334.
36. Bennett W.D. Effect of beta-adrenergic agonists on mucociliary clearance. J Allergy Clin Immunol 2002, 110:291-297.
37. Bennett W.D., Almond M.A., Zeman K.L., et al. Effect of salmeterol on mucociliary and cough clearance in chronic bronchitis. Pulm Pharmacol Ther 2006, 19:96-100.
38. Meyer T., Reitmeir P., Brand P., et al. Effects of formoterol and tiotropium bromide on mucus clearance in patients with COPD. Respir Med 2011, 105:900-906.
39. Crisafulli E., Coletti O., Costi S., et al. Effectiveness of erdosteine in elderly patients with bronchiectasis and hypersecretion: a 15-day, prospective, parallel, open-label, pilot study. Clin Ther 2007, 29:2001-2009.
40. Seagrave J., Albrecht H., Park Y.S., et al. Effect of guaifenesin on mucin production, rheology, and mucociliary transport in differentiated human airway epithelial cells. Exp Lung Res 2011, 37:606-614.